Titan Medical Inc.
TMDI · NASDAQ
12/31/2021 | 12/31/2020 | 12/31/2019 | 12/31/2018 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.07 | 0.06 | -0.24 | 0.01 |
| FCF Yield | -89.22% | -1.26% | -305.56% | -206.05% |
| EV / EBITDA | -0.78 | -4.02 | -0.35 | -0.89 |
| Quality | ||||
| ROIC | -40.02% | 209.80% | 356.00% | -536.84% |
| Gross Margin | 100.00% | 100.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 2.46 | 0.03 | 1.10 | 1.83 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -2,487.22% | 96.89% | -11.00% | -116.74% |
| Safety | ||||
| Net Debt / EBITDA | 2.22 | 0.99 | 0.02 | 0.00 |
| Interest Coverage | -117.42 | -21.16 | -98.07 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 150.41 | 1.31 | 0.00 | 0.00 |